Pfizer Medical

Communicating emerging, trusted scientific information to healthcare professionals (HCPs). Pfizer sponsored, intended for U.S. HCPs. Our community guidelines can be found here: pfi.sr/JJG

Pfizer Dermatology is at #AAD2026. Join us on March 28 at Bellco Theatre 3, Colorado Convention Center, Denver, for our late-breaking presentation to hear our latest data on #AtopicDermatitis. #Dermatology Learn more: pfi.sr/fGi

Join Pfizer Medical at #THSNA2026! We are proud to be sharing our latest #hemophilia research, including two poster presentations. Meet us at booth #314 to learn more. We look forward to connecting with you in Portland, Oregon

Watch Dr. Young share his perspective from #EAHAD2026, highlighting our long-standing commitment to patients living with #hemophilia. Explore the abstracts at pfi.sr/26e

Headed to ACC.26? Join us at the Pfizer Learning Labs for interactive, case-based discussions and peer-to-peer learning throughout the meeting. pfi.sr/fwg #ACC26 #Cardiology #ATTRCM

Join Pfizer Dermatology in Denver this March for #AAD2026. We are excited to present several posters and oral presentations on #AlopeciaAreata and #AtopicDermatitis. Hear from Dr. Eichenfield, who is looking forward to the congress. Register here: pfi.sr/xvm

New publication in the Journal of Headache and Pain evaluates the long-term safety and effectiveness of a CGRP receptor antagonist for migraine prevention in an open-label study. Full publication: pfi.sr/fwq #Neurotwitter #healthcare

#PfizerMedical is proud to present our latest research in #hemophilia resources at the #ISTH Academy. Explore the data at: pfi.sr/i26

Read a new publication presenting real-world evidence on the safety and effectiveness of a treatment in individuals with #sicklecelldisease (SCD) participating in two US registry studies. Learn More pfi.sr/f3N

"Blood clots (VTE) will always be symptomatic” That’s a common myth. Swipe through our myths vs facts sheets to learn what venous thromboembolism really is and why awareness matters. #BloodClotAwarenessMonth #stoptheclot

On #WorldObesityDay, Pfizer recognizes obesity as a complex disease & supports efforts to advance evidence-based care and improved outcomes for patients. See our short video with reminders about some key principles in the treatment of obesity.

A new post-hoc analysis reveals how treatment with a JAK inhibitor (JAKi) impacts itch relief and quality of life in patients with itch-dominant #AtopicDermatitis. Read the full publication in JEADV. #Dermatology #Eczema pfi.sr/fJb

Thank you for joining us at #ECCO2026. Click and learn more about our latest research in #UlcerativeColitis. pfi.sr/fid

GLP1 receptor agonists are effective for treating obesity, but around half of the patients discontinue therapy within 1 year. In clinical trials evaluating GLP-1 RA treatment discontinuation, about what percent of weight do patients regain in the next year? A knowledge check!

At #PfizerMedical, we are dedicated to supporting patients with rare diseases. Join us in raising awareness today for #RareDiseaseDay.

Pfizer Medical is proud to announce a new Independent Medical Education grant focused on Advances in Migraine Management. Submission Deadline: May 8 Together, let’s support HCP education on #migraine. pfi.sr/foD #MedEd #neurotwitter

New article in the Journal for Nurse Practitioners introduces a primary care migraine toolkit and highlights the mnemonic RATE—Recognize, Assess, Treat, Evaluate—to help in the diagnosis and management of migraine #neurotwitter pfi.sr/RATEpub

New migraine data: A post-hoc subgroup analysis across three randomized, placebocontrolled trials evaluating a CGRP receptor antagonist for the acute treatment of migraine in Black or African American adults. Full pub here: pfi.sr/CGRPpub #neurotwitter

Applications for the joint American Headache Society and Pfizer #QI program addressing quality gaps in headache medicine to create tools that drive measurable improvements in headache care are due by Feb 25! pfi.sr/MigraineQI25 #neurotwitter #AHSAM

Join our U.S. Field Medical Directors to explore our ASH 2025 hemophilia scientific data. Multiple sessions are scheduled throughout March, and we look forward to an engaging discussion with you! Register now at pfi.sr/reg1

Pfizer is pleased to announce a new Headache Medicine Fellowship grant. For more information, please visit: pfi.sr/xF4 Submission Deadline: April 6, 2026 Help us take on #migraine. #neurotwitter